studies (e.g., a CNS drug Thioridazine exhibited in vitro activity and is therefore included as a parent in Figure ). This being said, our own -likely, subjective -focus has been on drugs that might mitigate the viral infection itself (antivirals), those that can be in some way related to immune response accompanying serious COVID-19 infections (immunosuppressant, immunomodulatory, antiasthmatics, antirheumatic and anti-inflammatory agents), or mucolytics helpful in airway clearance .